Surgery Partners, Inc. (NASDAQ:SGRY) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its holdings in Surgery Partners, Inc. (NASDAQ:SGRY) by 6.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,241,865 shares of the company’s stock after selling 88,534 shares during the period. Victory Capital Management Inc. owned 0.98% of Surgery Partners worth $26,290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in SGRY. Principal Financial Group Inc. acquired a new stake in Surgery Partners in the 3rd quarter valued at about $1,469,000. State of New Jersey Common Pension Fund D acquired a new stake in Surgery Partners in the 3rd quarter valued at about $1,968,000. Versor Investments LP acquired a new stake in Surgery Partners in the 3rd quarter valued at about $271,000. WCM Investment Management LLC lifted its holdings in Surgery Partners by 0.3% in the 3rd quarter. WCM Investment Management LLC now owns 522,084 shares of the company’s stock valued at $16,665,000 after purchasing an additional 1,819 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Surgery Partners by 31.8% in the 3rd quarter. KBC Group NV now owns 2,385 shares of the company’s stock valued at $77,000 after purchasing an additional 576 shares in the last quarter.

Surgery Partners Trading Down 1.6 %

Shares of SGRY stock opened at $23.66 on Tuesday. The firm has a market cap of $3.01 billion, a P/E ratio of -49.29, a PEG ratio of 19.21 and a beta of 2.73. Surgery Partners, Inc. has a 1-year low of $19.50 and a 1-year high of $33.97. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. The firm’s 50-day simple moving average is $23.39 and its 200-day simple moving average is $26.25.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.38 by $0.01. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. As a group, equities analysts forecast that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Insider Activity at Surgery Partners

In related news, CFO David T. Doherty sold 13,641 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $25.61, for a total value of $349,346.01. Following the transaction, the chief financial officer now owns 108,862 shares in the company, valued at approximately $2,787,955.82. This trade represents a 11.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Harrison R. Bane sold 56,315 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the transaction, the insider now owns 107,037 shares in the company, valued at $2,744,428.68. The trade was a 34.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 96,733 shares of company stock worth $2,480,106. Company insiders own 2.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Royal Bank of Canada reduced their target price on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Bank of America assumed coverage on shares of Surgery Partners in a report on Monday, December 16th. They issued a “buy” rating and a $30.00 target price on the stock. Macquarie restated an “outperform” rating and issued a $34.00 target price on shares of Surgery Partners in a report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Surgery Partners presently has a consensus rating of “Moderate Buy” and an average price target of $36.75.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.